A simplified three-times weekly daptomycin dosing regimen for chronic hemodialysis patients

Expert Review of Anti-Infective Therapy

Volumn 8, Issue 1, 2010, Pages 11-14

  Burkhardt, Olaf ^a   Kielstein, Jan T ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

daptomycin; dialysis; end stage renal disease; infection; pharmacokinetics

Indexed keywords

DAPTOMYCIN;

AREA UNDER THE CURVE; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG SAFETY; HEMODIALYSIS; HUMAN; LONG TERM CARE; MAXIMUM PLASMA CONCENTRATION; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; NOTE; SINGLE DRUG DOSE; TIME TO MAXIMUM PLASMA CONCENTRATION;

EID: 79951923901     PISSN: 14787210     EISSN: 17448336     Source Type: Journal    
DOI: 10.1586/eri.09.121     Document Type: Note

References (17)

1. Salama NN, Segal JH, Churchwell MD et al. Intradialytic administration of daptomycin in end stage renal disease patients on hemodialysis. Clin. J. Am. Soc. Nephrol. 4, 1190-1194 (2009).
2. Lysaght MJ. Maintenance dialysis population dynamics: current trends and long-term implications. J. Am. Soc. Nephrol. 13(Suppl. 1), S37-S40 (2002). (Pubitemid 34008176)
3. Amann K, Wanner C, Ritz E. Cross-talk between the kidney and the cardiovascular system. J. Am. Soc. Nephrol. 17, 2112-2119 (2006). (Pubitemid 44141900)
4. Sarnak MJ, Jaber BL. Pulmonary infectious mortality among patients with end-stage renal disease. Chest 120, 1883-1887 (2001). (Pubitemid 34053449)
5. Sarnak MJ, Jaber BL. Mortality caused by sepsis in patients with end-stage renal disease compared with the general population. Kidney Int. 58, 1758-1764 (2000).
6. Dalrymple LS, Go AS. Epidemiology of acute infections among patients with chronic kidney disease. Clin. J. Am. Soc. Nephrol. 3, 1487-1493 (2008).
7. Chavers BM, Solid CA, Gilbertson DT, Collins AJ. Infection-related hospitalization rates in pediatric versus adult patients with end-stage renal disease in the United States. J. Am. Soc. Nephrol. 18, 952-959 (2007). (Pubitemid 46434512)
8. CDC. Invasive methicillin-resistant Staphylococcus aureus infections among dialysis patients-United States, 2005. MMWR Morb. Mortal. Wkly Rep. 56, 197-199 (2007).
9. Sader HS, Fritsche TR, Jones RN. Antimicrobial activity of daptomycin and selected comparators tested against bloodstream Staphylococcus aureus isolates from hemodialysis patients. Int. J. Infect. Dis. 13, 291-295 (2009).
10. Roveta S, Marchese A, Schito GC. Activity of daptomycin on bioflms produced on a plastic support by Staphylococcus spp. Int. J. Antimicrob. Agents 31, 321-328 (2008).
11. Dvorchik BH, Brazier D, DeBruin MF, Arbeit RD. Daptomycin pharmacokinetics and safety following administration of escalating doses once daily to healthy subjects. Antimicrob. Agents Chemother. 47, 1318-1323 (2003). (Pubitemid 36368592)
12. Dvorchik B, Arbeit RD, Chung J, Liu S, Knebel W, Kastrissios H. Population pharmacokinetics of daptomycin. Antimicrob. Agents Chemother. 48, 2799-2807 (2004). (Pubitemid 38989139)
13. Kielstein JT, Oye C, Bode-Boeger SM et al. Dosing of daptomycin in intensive care unit patients with acute kidney injury undergoing extended dialysis-a pharmacokinetic study. Nephrol. Dialysis Transplant. DOI: 10.1093/ndt/gfp704 (2009) (Epub ahead of print).
14. Churchwell MD, Pasko DA, Mueller BA. Daptomycin clearance during modeled continuous renal replacement therapy. Blood Purif. 24, 548-554 (2006). (Pubitemid 46030098)
15. Goedecke VA, Clajus C, Burkhardt O et al. Pharmacokinetics and dialysate levels of daptomycin given intravenously in a peritoneal dialysis patient. Scand. J. Infect. Dis. 41, 155-157 (2009).
16. Huen SC, Hall I, Topal J, Mahnensmith RL, Brewster UC, Abu-Alfa AK. Successful use of intraperitoneal daptomycin in the treatment of vancomycin-resistant enterococcus peritonitis. Am. J. Kidney Dis. 54, 538-541 (2009).
17. Kielstein JT, Czock D, Schopke T et al. Pharmacokinetics and total elimination of meropenem and vancomycin in intensive care unit patients undergoing extended daily dialysis. Crit. Care Med. 34, 51-56 (2006). (Pubitemid 43032379)